Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | $7.00 | Hold → Buy | Truist |
| 12/10/2024 | $10.00 | Buy | H.C. Wainwright |
| 11/3/2023 | $6.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 4/28/2023 | $5.00 → $1.50 | Neutral → Underperform | BofA Securities |
| 2/27/2023 | $16.00 | Neutral → Outperform | Wedbush |
| 1/6/2023 | $8.00 → $5.00 | Buy → Neutral | BofA Securities |
| 6/13/2022 | $5.00 | Neutral | Wedbush |
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval Isaralgagene civaparvovec showed a favorable safety and tolerability profile Sangamo intends to submit a Biologics License Application (BLA) in 2026 Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced positive topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry diseas
Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments, plus tiered royalties on potential net sales. Announced derisking milestones in pathway to anticipated biologics license application (BLA) submission for isaralgagene civaparvovec in Fabry disease, including all patients having passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway, and productive Type B Chemistry, Manufacturing and Con
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock